Signalment, clinicopathological findings, management practices and comorbidities in cats with diabetes mellitus in Germany: cross-sectional study of 144 cases
- PMID: 39772828
- PMCID: PMC11707777
- DOI: 10.1177/1098612X241303303
Signalment, clinicopathological findings, management practices and comorbidities in cats with diabetes mellitus in Germany: cross-sectional study of 144 cases
Abstract
Objectives: The aim of this study was to describe signalment, clinicopathological findings, management practices and the occurrence of comorbidities in feline diabetes mellitus (DM) in Germany.
Methods: This was a cross-sectional study using questionnaires and laboratory submissions to a commercial laboratory, Antech Lab Germany, between May 2021 and July 2022. Inclusion criteria were diagnosis of DM by the attending veterinarian and submission of a completed questionnaire besides blood samples. Laboratory testing included haematology, serum biochemistry, concentration of total thyroxine (TT4), insulin-like growth factor 1 (IGF-1), cobalamin (COB), fructosamine, b-hydroxybutyrate and DGGR (1,2-O-dilauryl-rac-glycero-3-glutaric acid-[6'-methylresorufin] ester) lipase activity. Data are presented as the median (range) and analysed by non-parametric tests. P <0.05 was considered statistically significant.
Results: The median (range) age of the 144 diabetic cats at diagnosis was 11 years (0.9-18.7), 66.4% were male, 84.6% were domestic shorthair, 50.4% were currently overweight and 61.5% were previously overweight (body condition score >5/9). Most cats were treated with insulin (84%), most commonly protamine zinc insulin (57.5%). Blood glucose curves or continuous glucose monitoring alone or in combination with other methods were performed to adjust insulin therapy in 70.6% of cats. Based on questionnaires, 78.6% were poorly controlled and 21.4% were well controlled. Increased TT4 occurred in 3/139 and hyperthyroidism was known in 5/139 cats (frequency of known/suspected hyperthyroidism: 5.8% [n = 8/139]); 17.5% (n = 17/97) had increased IGF-1 (IGF-1 >746 ng/ml, cut-off for hypersomatotropism with the chemiluminescence assay used in this study); 24.5% (n = 34/139) had COB <295.2 pmol/l and 54.2% (n = 78/144) had increased DGGR. Cats with IGF-1 >746 ng/ml were receiving a higher insulin dose than cats with IGF-1 ≤746 ng/ml (median 1.63 vs 0.86 U/kg/day, P = 0.018).
Conclusion and relevance: Increased DGGR and increased IGF-1 indicating hypersomatotropism are common in diabetic cats and should be tested for. Almost one-quarter of diabetic cats might require COB supplementation.
Keywords: Cobalamin; hypersomatotropism; hyperthyroidism; hypocobalaminaemia; insulin-like growth factor 1; pancreatitis; vitamin B12.
Conflict of interest statement
Conflict of interestThe laboratory data used in this study were provided by Antech Lab Germany. Judith Langenstein is an employee of Antech Lab Germany GmbH.
References
-
- Panciera DL, Thomas CB, Eicker SW, et al.. Epizootiologic patterns of diabetes mellitus in cats: 333 cases (1980–1986). J Am Vet Med Assoc 1990; 197: 1504–1508. - PubMed
-
- Rand JS, Bobbermien LM, Hendrikz JK, et al.. Over representation of Burmese cats with diabetes mellitus. Aust Vet J 1997; 75: 402–405. - PubMed
-
- Lederer R, Rand JS, Jonsson NN, et al.. Frequency of feline diabetes mellitus and breed predisposition in domestic cats in Australia. Vet J 2009; 179: 254–258. - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
